We’re excited to share that Inductive Bio has joined the OASIS Consortium, a collaborative effort focused on predicting liver toxicity from advanced in vitro assays within the Health and Environmental Sciences Institute (HESI).
As part of OASIS, we’ll be helping assess how different pharmacokinetic (PK) approaches define drug exposure for DILI prediction, including exposure estimates powered by Inductive’s Beacon-1 ADME models. This work builds on the foundation of our ARPA-H CATALYST award, where we’re developing next-generation in vitro and AI methods for liver and cardiac safety prediction along with our collaborators Amgen Cincinnati Children's Baylor College of Medicine and Torch Bio.
A key challenge in toxicology modeling is that clinical risk depends on both mechanistic hazards and exposure. We believe exposure-aware toxicity models are essential for generating predictions that are both accurate and clinically meaningful, and we’re excited to contribute to the consortium’s efforts in this area.
As part of OASIS, we’ll be helping assess how different pharmacokinetic (PK) approaches define drug exposure for DILI prediction, including exposure estimates powered by Inductive’s Beacon-1 ADME models. This work builds on the foundation of our ARPA-H CATALYST award, where we’re developing next-generation in vitro and AI methods for liver and cardiac safety prediction along with our collaborators Amgen Cincinnati Children's Baylor College of Medicine and Torch Bio.
A key challenge in toxicology modeling is that clinical risk depends on both mechanistic hazards and exposure. We believe exposure-aware toxicity models are essential for generating predictions that are both accurate and clinically meaningful, and we’re excited to contribute to the consortium’s efforts in this area.
